Literature DB >> 16166948

Chemotherapy for advanced non-small-cell lung cancer.

Luis E Raez1, Rogerio Lilenbaum.   

Abstract

The management of patients with advanced non-small-cell lung cancer has changed considerably in the last decade. Chemotherapy prolongs survival and improves quality of life in patients with a good performance status and appears to improve disease-related symptoms in patients with a lower performance status. Platinum-based doublets remain the standard regimen, but nonplatinum combinations are reasonable alternatives. Newer agents with novel mechanisms of action have opened new areas of clinical research and are likely to further improve the outcome of patients with advanced non-small-cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16166948

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


  6 in total

1.  Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.

Authors:  Jianli Zhang; Yue Hong; Jie Shen
Journal:  Tumour Biol       Date:  2015-02-20

2.  Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.

Authors:  Dezhi Liu; Ling Yan; Lan Wang; Weicheng Tai; Weili Wang; Changbin Yang
Journal:  Oncol Lett       Date:  2014-10-09       Impact factor: 2.967

3.  Astragalin-induced cell death is caspase-dependent and enhances the susceptibility of lung cancer cells to tumor necrosis factor by inhibiting the NF-кB pathway.

Authors:  Minghui Chen; Fangfang Cai; Daolong Zha; Xueshi Wang; Wenjing Zhang; Yan He; Qilai Huang; Hongqin Zhuang; Zi-Chun Hua
Journal:  Oncotarget       Date:  2017-04-18

4.  Promising Anticancer Effect of Aurisin A Against the Human Lung Cancer A549 Cell Line.

Authors:  Parichart Boueroy; Thidarut Boonmars; Somdej Kanokmedhakul; Sorujsiri Chareonsudjai; Ratsami Lekphrom; Suphachira Srichangwang
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

5.  AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth.

Authors:  Ying-Chen Xia; Jian-Hua Zha; Yong-Hua Sang; Hui Yin; Guo-Qiu Xu; Jie Zhen; Yan Zhang; Ben-Tong Yu
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

6.  miR-124 and miR-142 enhance cisplatin sensitivity of non-small cell lung cancer cells through repressing autophagy via directly targeting SIRT1.

Authors:  Xiang Song; Fanyi Kong; Zhenfeng Zong; Mingming Ren; Qingjun Meng; Yanguang Li; Zhen Sun
Journal:  RSC Adv       Date:  2019-02-12       Impact factor: 3.361
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.